Singulex Receives European Patent Expanding Use of Biomarkers Troponin I and T to Detect Cardiac Health Status With High-Sensitivity Methods
ALAMEDA, Calif., 2015-11-05 15:00 CET (GLOBE NEWSWIRE) -- Singulex, Inc., the developer of Single Molecule Counting technology for use in both medical practice diagnostics and scientific research, has received from the European Patent Office (EPO) a key patent (EP2002260) for use of the biomarkers troponin I and T to detect cardiac damage in humans using any high-sensitivity method. The new patent complements four previous cardiac troponin patents granted to Singulex by the EPO and US Patent and Trademark Office that include claims for determining cardiovascular health status in humans with high-sensitivity assays.
"The granting of this European patent recognizes the significant scientific discoveries made by Singulex about the role of troponin as a marker of cardiovascular health, an area to which we are deeply committed. We look forward to applying our expanding intellectual property, via our Single Molecule Counting technology, to enable more precision in determining the heart health of patients, even if they have not had apparent heart attacks. Such information should help physicians in the proactive management of their patients' health," said Guido Baechler, President and Chief Executive Officer of Singulex.
Singulex was the first to discover that very low levels of the proteins troponin I or troponin T are detectable in the blood of healthy patients, using the company's high-sensitivity Single Molecule Counting technology, and has demonstrated in numerous peer-reviewed publications that measuring such low levels is clinically meaningful, can help determine patients' heart health status and aid in managing their risk for future cardiovascular-related disease or death.
When heart muscle is damaged, such as during a heart attack, significant levels of troponin leak into the blood stream. Existing troponin-based blood tests are used routinely in clinical practice to determine if patients have suffered a heart attack, but are not able to measure low troponin levels in patients without substantial heart muscle damage. Singulex's patents cover high sensitivity assays that measure these low troponin levels.
Singulex intends to include cardiac health diagnostics that measure both low- and high-levels of troponin in its European launch of the Sgx ClarityTM System, a high sensitivity immunoassay diagnostic platform, planned for 2016. Through pioneering research and development, Singulex has steadily added new knowledge about the significance of using troponin to gauge cardiovascular health, and received the patents EP2386858, US7838250, US8343728 and US8535895, since 2010.
The estimated global market for in vitro diagnostic tests for cardiac biomarkers was nearly $4 billion in 2013, with an anticipated growth to $7.2 billion by 2018. The World Health Organization estimates that cardiovascular diseases, including those of the blood vessels supplying the heart muscle and the brain, are the leading cause of death globally, killing about 17.5 million people in 2012, including an estimated 7.4 million due to coronary heart disease.
For more information about peer-reviewed scientific journal articles and presentations, visit http://www.singulex.com/scientific-journals-publications.
About Singulex, Inc.
Singulex is the developer of Single Molecule Counting technology for clinical diagnostics and scientific discovery. Singulex's proprietary SMCTM technology enables physicians and scientists to detect biomarkers of disease that were previously undetectable. Powered by SMC technology, Singulex's ultrasensitive lab testing services are transforming patient care from reactive disease treatment to proactive health management.
The Singulex Clinical Lab Testing Services consist of a CLIA-licensed and CAP-accredited laboratory that currently provides a comprehensive menu of advanced cardiovascular disease testing utilizing SMC technology. Singulex is currently developing the Sgx Clarity™ System, a fully-automated in vitro diagnostics system that will bring the benefits of SMC technology to hospital and reference labs worldwide. For more information, please visit www.singulex.com.
Red House Consulting
Om NASDAQ OMX
NASDAQ OMX (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra NASDAQ OMX
Registrer deg med din epostadresse under for å få de nyeste sakene fra NASDAQ OMX på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra NASDAQ OMX
Telix Pharmaceuticals Limited Launches $50 Million Underwritten Initial Public Offering (ASX: TLX)23.10.2017 23:00 | Pressemelding
MELBOURNE, Australia, Oct. 23, 2017 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (Telix, the Company), an Australian biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or "molecularly-targeted radiation" (MTR), is pleased to announce the opening of its Initial Public Offering (IPO or Offer) to raise A$50 million. The IPO is an offer by Telix for the issue of 77.0 million shares at $0.65 per share and is fully underwritten by the Lead Managers, Taylor Collison Limited and Wilsons Corporate Finance Limited. The IPO has been strongly supported by the Company's existing shareholders, which include both industry partners and domestic institutional investors, such as Acorn Capital, CVC, Monash Investors, Viburnum Funds, Allan Moss and Alium Capital Management. With this Offer, Telix will further strengthen its Australian and international institutional shareholder base, including the addition of Fidel
Brookfield Asset Management Notice of 2017 Q3 Results Conference Call and Webcast23.10.2017 17:03 | Pressemelding
Date: Thursday, November 9, 2017 Time: 11:00 a.m. (Eastern Time) BROOKFIELD, News, Oct. 23, 2017 (GLOBE NEWSWIRE) -- You are invited to participate in Brookfield Asset Management's 2017 Third Quarter Conference Call & Webcast on Thursday, November 9, 2017 at 11:00 a.m. (Eastern Time) to discuss with members of senior management our results and current business initiatives. These results will be released on November 9th before 7:00 a.m. (Eastern Time) and will be available following the release on our website at www.brookfield.com "News - Press Releases." The Conference Call will also be Webcast live on our website, where it will be archived for future reference. To participate in the Conference Call, please dial 1-800-319-4610 toll free in North America, or for overseas calls please dial 1-604-638-5340 at approximately 10:50 a.m. The Conference Call will also be Webcast live at http://servic
Rapid Micro Biosystems Awarded a Contract by Biomedical Advanced Research and Development Authority (BARDA) for the Implementation of a Rapid Sterility Test for Vaccines23.10.2017 13:00 | Pressemelding
LOWELL, Mass., Oct. 23, 2017 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, a leading provider of automated, non-destructive, rapid microbial detection, is pleased to announce the receipt of a $7.3 million contract from the Biomedical Advanced Research and Development Authority (BARDA) for the implementation of a rapid sterility test for vaccines. This awarded grant is part of BARDA's Advance Development of Medical Countermeasures for Pandemic Influenza, which focuses on improving the government's responsiveness to future pandemic threats. When combined with Rapid Micro Biosystems' automated Growth Direct(TM) detection system, the rapid sterility test will result in faster release of vaccines and other sterile products. Timely delivery of these products carries multiple public benefits, principally in facilitating rapid responses to pandemic or emerging infections, agents of bioterrorism, and availability of life saving medicines. "Our continuing relationship with BARDA demonstrate
Xehar Fashion App Ditches the Shopping Cart and Picks Up Speed23.10.2017 12:00 | Pressemelding
New fast fashion app will shorten the checkout time by removing the shopping cart altogether. PLAYA VISTA, Calif., Oct. 23, 2017 (GLOBE NEWSWIRE) -- Fashion tech company Xehar, today announces they will be removing the shopping cart from their Xehar shopping app. For millennial women shoppers who are interested in fashion but are frustrated with the online shopping experience, the Xehar app is their solution. "Xehar has found a way to increase conversion for app purchases by simply removing the function of the shopping cart," says Hadari Oshri, founder and CEO of Xehar. "Within the app, users select complete outfits and purchase with ease. By removing the shopping cart we are reducing friction and speeding up the checkout process." A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/c58ce496-70e7-4675-8f59-3e39725708c4 Website and app owners deal with the reality of shopping cart abandonment
BroadSoft Announces New Integrated and Intelligent Cloud Communication and Collaboration Experiences23.10.2017 07:30 | Pressemelding
Upgrades deliver on the BroadSoft Business cloud unified communication vision to deliver intuitive, consistent client experiences across the entire suite and reinvent workflow efficiencies PHOENIX, Oct. 23, 2017 (GLOBE NEWSWIRE) -- BroadSoft, Inc. (NASDAQ:BSFT) a global market share leader in cloud business software for unified communication as a service (UCaaS), and provider of collaboration and contact center as a service (CCaaS), today unveiled several enhancements to its BroadSoft Business portfolio at its annual user conference, BroadSoft Connections. Now leveraging a microservices architecture, BroadSoft Business offers updated app experiences and next-generation capabilities across the BroadSoft Business applications, UC-One, Team-One and CC-One. A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/0df82bc5-5481-4429-9586-bba075849626 Business users today are overwhelmed with managing their workfl
BroadSoft Business Cloud PBX, Team Collaboration and Contact Center Apps Now Available for Multinational Enterprises23.10.2017 07:30 | Pressemelding
New, localized data centers offer multinational enterprise customers secure, multi-language calling and collaboration between global offices via a single, borderless BroadCloud platform PHOENIX, Oct. 23, 2017 (GLOBE NEWSWIRE) -- BroadSoft, Inc. (NASDAQ:BSFT) a global market share leader in cloud business software for unified communication as a service (UCaaS), and provider of collaboration and contact center as a service (CCaaS), today announced its BroadSoft Business cloud communication suite is available worldwide via several new BroadCloud ® data centers throughout EMEA and APAC. This expansion allows multinational enterprises to rely on a single provider across their international locations to collaborate with peers and customers around the globe, while meeting full regulatory and security compliance across different countries. A recent McKinsey Global Institute 2016 report noted that cross-border bandwidth is projected to increase nine times over the next
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom